Coldstream Capital Management Inc. Purchases 516 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Coldstream Capital Management Inc. grew its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 15.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,917 shares of the company’s stock after acquiring an additional 516 shares during the quarter. Coldstream Capital Management Inc.’s holdings in Neurocrine Biosciences were worth $452,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Sumitomo Mitsui DS Asset Management Company Ltd increased its stake in Neurocrine Biosciences by 0.8% during the 2nd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 11,436 shares of the company’s stock valued at $1,574,000 after purchasing an additional 90 shares in the last quarter. Fifth Third Bancorp grew its holdings in shares of Neurocrine Biosciences by 14.7% during the second quarter. Fifth Third Bancorp now owns 716 shares of the company’s stock valued at $99,000 after buying an additional 92 shares during the last quarter. Total Clarity Wealth Management Inc. increased its position in shares of Neurocrine Biosciences by 4.3% during the second quarter. Total Clarity Wealth Management Inc. now owns 2,433 shares of the company’s stock worth $335,000 after acquiring an additional 100 shares in the last quarter. Commerce Bank raised its holdings in shares of Neurocrine Biosciences by 2.6% in the 3rd quarter. Commerce Bank now owns 4,199 shares of the company’s stock worth $484,000 after acquiring an additional 108 shares during the last quarter. Finally, Caprock Group LLC lifted its position in Neurocrine Biosciences by 7.0% in the 2nd quarter. Caprock Group LLC now owns 1,669 shares of the company’s stock valued at $230,000 after acquiring an additional 109 shares in the last quarter. Institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Stock Performance

Shares of Neurocrine Biosciences stock opened at $126.70 on Friday. The stock has a market capitalization of $12.83 billion, a P/E ratio of 33.97 and a beta of 0.34. Neurocrine Biosciences, Inc. has a 52-week low of $110.95 and a 52-week high of $157.98. The stock’s 50-day simple moving average is $121.75 and its 200 day simple moving average is $130.62.

Wall Street Analysts Forecast Growth

A number of analysts have commented on NBIX shares. Royal Bank of Canada decreased their price objective on Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating for the company in a report on Friday, October 4th. Barclays lowered their price target on Neurocrine Biosciences from $180.00 to $160.00 and set an “overweight” rating for the company in a research report on Monday, September 9th. Piper Sandler raised shares of Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $131.00 to $159.00 in a report on Thursday, August 29th. Raymond James reiterated an “outperform” rating and issued a $155.00 target price on shares of Neurocrine Biosciences in a report on Thursday, October 10th. Finally, Needham & Company LLC restated a “hold” rating on shares of Neurocrine Biosciences in a report on Monday, November 11th. Five equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $165.18.

Insider Activity at Neurocrine Biosciences

In related news, insider Jude Onyia sold 2,331 shares of the business’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $126.29, for a total transaction of $294,381.99. Following the sale, the insider now directly owns 15,449 shares in the company, valued at approximately $1,951,054.21. The trade was a 13.11 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.30% of the stock is currently owned by corporate insiders.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.